Soluble β-amyloid1-40 induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic Synapses

Journal of Neuroscience

Volumn 25, Issue 48, 2005, Pages 11061-11070

  Roselli, F ^a,b   Tirard, M ^a,e   Lu, J ^a,f   Hutzler, P ^c   Lamberti, P ^b   Livrea, P ^b   Morabito, M ^d   Almeida, O F X ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF BARI   (Italy)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

A peptide; AMPA receptor; Amyloid ; cdk5; Glutamate receptor; Metabotropic glutamate receptor; NMDA receptor; Phosphorylation; Proteasome; PSD 95; Synaptic plasticity

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN[1-40]; CYCLIN DEPENDENT KINASE 5; GLUTAMATE RECEPTOR 2; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEASOME; AMYLOID BETA PROTEIN; CALCIUM; CDK5 PROTEIN, RAT; DLGH4 PROTEIN, RAT; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; MEMBRANE PROTEIN; N METHYLASPARTIC ACID; NERVE PROTEIN; PEPTIDE FRAGMENT; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; NERVE CELL CULTURE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SYNAPSE; ANIMAL; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG ANTAGONISM; FRONTAL LOBE; HUMAN; METABOLISM; NERVE CELL; PHYSIOLOGY; SOLUBILITY; WISTAR RAT;

AMYLOID BETA-PROTEIN; ANIMALS; CALCIUM; CELL MEMBRANE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; DOWN-REGULATION; FRONTAL LOBE; GLUTAMIC ACID; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SOLUBILITY; SYNAPSES;

EID: 30644475475     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3034-05.2005     Document Type: Article

References (70)

1. Bingol B, Schuman E (2004) A proteasome-sensitive connection between PSD-95 and GluR1 endocytosis. Neuropharmacology 47:755-763.
2. Bitan G, Lomakin A, Teplow DB (2001) Amyloid β protein oligomerization prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 276:35176-35184.
3. Bitan G, Vollers SS, Teplow DB (2003) Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 278:34882-34889.
4. Bredt D, Nicoll R (2003) AMPA receptor trafficking at excitatory synapses. Neuron 40:361-379.
5. Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, Bredt DS, Nicoll RA (2000) Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408:936-943.
6. Chen QS, Kagan BL, Hirakura Y, XieCW (2000) Impairment of hippocampal long-term potentiation by Alzheimer beta peptides. J Neurosci Res 60:65-72.
7. Christopherson KS, Sweeney NT, Craven SE, Kang R, El-Husseini AE, Bredt D (2003) Lipid- and protein-mediated multimerization of PSD-95: implication for receptor clustering and assembly of synaptic protein networks. J Cell Sci 16:3213-3219.
8. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84.
9. Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24:1023-1027.
10. Coleman PD, Federoff H, Kurlan R (2004) A focus on synapse for neuro-protection in Alzheimer disease and other dementias. Neurology 63:1155-1162.
11. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg KL, Lu H, Bear MF, Scott JD (2003) Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 40:595- 607.
12. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OFX (2005) Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10:790-798.
13. Cruz JC, Tsai LH (2004) Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10:452-458.
14. Deiva K, Geeraerts T, Salim H, Leclerc P, Hery C, Hugel B, Freyssinet JM, Tardieu M (2004) Fractalkine reduces N-methyl-D-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur J Neurosci 20:3222-3232.
15. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severitiy. Ann Neurol 27:457-464.
16. Dhavan R, Tsai LH (2001) A decade of cdk-5. Nat Rev Neurosci 2:749-759.
17. DiAntonio A, Hicke L (2004) Ubiquitin-dependent regulation of the synapse. Annu Rev Neurosci 27:223-246.
18. Dong YN, Waxman EA, Lynch DR (2004) Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit controls calpain-mediated cleavage of the NMDA receptor. J Neurosci 24:1035-1045.
19. Ehlers MD (2003) Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 6:231-242.
20. Ehrlich I, Malinow R (2004) Postsynaptic density 95 controls AMPA receptor incorporation during long term potentiation and experience driven synaptic plasticity. J Neurosci 24:916 -927.
21. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS (2000) PSD-95 involvement in maturation of excitatory synapses. Science 290:1364-1368.
22. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric Aligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422.
23. Grassi S, Frondaroli A, Pettorossi VE (2002) Different metabotropic glutamate receptors play opposite roles in synaptic plasticity of the rat medial vestibular nuclei. J Physiol (Lond) 543:795-806.
24. Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid and memory in aging and mild cognitive impairment. Arch Neurol 60:729 -736.
25. Humbert S, Lanier LM, Tsai LH (2000) Synaptic localization of p39, a neuronal activator of cdk5. NeuroReport 11:2213-2216.
26. Iwamoto T, Yamada Y, Hori K, Watanabe Y, Sobue K, Inui M (2004) Differential modulation of NR1-NR2A and NR1-NR2B subtypes of NMDA receptor by PDZ domain-containing proteins. J Neurochem 89:100-108.
27. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925-937.
28. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T (2004) Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35in cultured rat hippocampal neurons. Neurosci Lett 368:181-185.
29. Kim E, Sheng M (2004) PDZ domain proteins of synapse. Nat Neurosci Rev 5:771-781.
30. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ (2004) Soluble arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 19:2839-2846.
31. Lacor P, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Kraft GA, Klein WL (2004) Synaptic targeting by Alzheimer's related amyloid oligomers. J Neurosci 24:10191-10200.
32. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft CA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
33. Lavezzari G, McCallum J, Lee R, Roche KW (2003) Differential binding of the AP-2 adaptor complex and PSD-95 to the C-terminus of the NMDA receptor subunit NR2B regulates surface expression. Neuropharmacology 45:729-737.
34. Li B, Otsu Y, Murphy TH, Raymond LA (2003) Developmental decrease in NMDA receptor desensitization associated with shift to synapse and interaction with postsynaptic density-95. J Neurosci 23:11244-11254.
35. Lin Y, Skeberdis VA, Francesconi A, Bennett MV, Zukin RS (2004) Postsynaptic density protein-95 regulates NMDA channel gating and surface expression. J Neurosci 24:10138-10148.
36. Liu XB, Murray KD, Jones EG (2004) Switching of NMDA receptor 2A and 2B subunits at thalamic and corical synapses during early postnatal development. J Neurosci 24:8885-8895.
37. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid-β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862.
38. Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. Neuron 44:5-21.
39. Mattson M (2004) Pathways toward and away from Alzheimer's disease. Nature 430:631-639.
40. McGee AW, Bredt DS (2003) Assembly and plasticity of the glutamatergic postsynaptic specialization. Curr Opin Neurobiol 13:111-118.
41. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191-199.
42. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severiy of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
43. Migaud M, Charleswoth P, Dempster M, Webster LC, Watabe AM, Makhinson M, He Y, Ramsay MF, Morris RGM, Morrison JH, O'Dell TJ, Grant SGN (1998) Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396:433-439.
44. Morabito M, Sheng M, Tsai LH (2004) Cyclin dependent kinase 5 phosphorylates the N-terminal domain of postsynaptic density protein PSD-95 in neurons. J Neurosci 24:865-876.
45. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST (2004) A novel cdk-5 dependent pathway for regulating gsk3 activity and kinesin-driven motility in neurons. EMBO J 23:2235-2245.
46. Niethammer M, Kim E, Sheng M (1996) Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 16:2157-2163.
47. Niethammer M, Smith DS, Ayala R, Peng J, Ko J, Lee MS, Morabito M, Tsai LH (2000) NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron 28:697-711.
48. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple transgenic model of Alzheimer disease with plaques and tangles: intracellular A-beta and synaptic dysfunction. Neuron 39:409-421.
49. Okabe S, Kim HD, Miwa A, Kuriu T, Okado H (1999) Continual remodelling of postsynaptic density and its regulation by synaptic activity. Nat Neurosci 2:804-811.
50. O'Nuallain B, Williams AD, Westermark P, Wetzel R (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279:17490-17499.
51. Pizzi M, Boroni F, Bianchetti A, Moraitis C, Sarnico I, Benarese M, Goffi F, Valerio A, Spano P (2002) Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. Eur J Neurosci 16:2342-2350.
52. Richardson JC, Kendal CE, Anderson R, Priest F, Gower E, Soden P, Gray R, Topps S, Howlett DR, Lavender D, Clarke NJ, Barnes JC, Haworth R, Stewart MG, Rupniak HT (2003) Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 122:213-228.
53. Roche KW, Standley S, McCallum J, Dune Ly C, Ehlers MD, Wenthold RJ (2001) Molecular determinants of NMDA receptor internalization. Nat Neurosci 4:794-802.
54. Sabio G, Reuver S, Feijoo C, Hasegawa M, Thomas GM, Centeno F, Kuhlendahl S, Leal-Ortiz S, Goedert M, Garner C, Cuenda A (2004) Stress- and mitogen-induced phosphorylation of the synapse associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. Biochem J 380:19 -30.
55. Schnell E, Sizemore M, Karimzadegan S, Chen L, Bredt DS, Nicoll RA (2002) Direct interaction between PSD-95 and stargazin control synaptic AMPA receptor number. Proc Natl Acad Sci USA 99:13902-13907.
56. Selkoe D (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
57. Snyder EM, Nong Y, Almeida GC, Paul S, Moran T, Choi EY, Nairns AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8:1051-1058.
58. Stein V, House DR, Bredt DS, Nicoll RA (2003) Postsynaptic density-95 mimics and occludes hippocampal long-term potentiation and enhances long-term depression. J Neurosci 23:5503-5506.
59. Stine BW, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J Biol Chem 278:11612-11622.
60. Tirard M, Jasbinsek J, Almeida OFX, Michaelidis TM (2004) The manifold actions of the protein inhibitor of activated STAT proteins on the transcriptional activity of mineralocorticoid and glucocorticoid receptors in neural cells. J Mol Endocrinol 32:825-841.
61. Todd PK, Mack KJ, Malter JS (2003) The fragile X mental retardation protein is required for type I metabotropic glutamate receptor dependent translation of PSD-95. Proc Natl Acad Sci USA 24:14374-14378.
62. Turrigiano GC (1999) Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci 22:221-227.
63. Walsh D, Selkoe DS (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
64. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272:22364-22372.
65. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe (2002) Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation. Nature 426:535-539.
66. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta-amyloid (1- 42) inhibit long-term potentiation but not long term depression in rat dentate gyrus. Brain Res 924:133-140.
67. Wang QW, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally occurring secreted and synthetic amyloid-peptide in hippocampal slices is mediated by activation of the kinases c-jun terminal kinases, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378.
68. Wilquet V, De Strooper B (2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14:582-588.
69. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25:1071-1080.
70. Ye C, Walsh D, Selkoe D, HartleyDM (2004) Amyloid beta protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 366:320-325.